The present application relates to the preparation of cyclohexyl-alkyl carbinols, including 1-(cyclohex-3-en-1-yl)-2-methylpropan-1-ol, which possesses a minty aroma that can be described as fresh, invigorating, and menthol-like, and also possesses cooling properties. The use of cyclohexyl-alkyl carbinols as readily accessible and cost effective fragrance, flavor, and cooling ingredients, and potential applications thereof is also described.

Process for the continuous production of an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ,-unsaturated carbonyl compound with hydrogen in the presence of a homogeneous rhodium catalyst that has at least one chiral ligand, wherein a liquid reaction mixture comprising the prochiral ,-unsaturated carbonyl compound is subjected in a first, backmixed reactor to a gas/liquid two-phase hydrogenation, and the liquid reaction mixture is then further hydrogenated in a second reactor, wherein the prochiral ,-unsaturated carbonyl compound is employed in the first reactor in a concentration from 3% to 20% by weight. The process allows a high total conversion to the prochiral ,-unsaturated carbonyl compound.

Process for the continuous production of an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ,-unsaturated carbonyl compound with hydrogen in the presence of a homogeneous rhodium catalyst that has at least one chiral ligand, wherein a liquid reaction mixture comprising the prochiral ,-unsaturated carbonyl compound is subjected in a first, backmixed reactor to a gas/liquid two-phase hydrogenation, and the liquid reaction mixture is then further hydrogenated in a second reactor, wherein the prochiral ,-unsaturated carbonyl compound is employed in the first reactor in a concentration from 3% to 20% by weight. The process allows a high total conversion to the prochiral ,-unsaturated carbonyl compound.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

A process for purifying a crude composition includes a monoterpene compound selected from the group consisting of monocyclic monoterpene alcohols, monocyclic monoterpene ketones, bicyclic epoxy monoterpenes and mixtures of two or more of the aforementioned compounds, such as preferably a monocyclic monoterpene alcohol. The process comprises performing a layer crystallization with a melt of the crude composition, and the melt of the crude composition subjected to the layer crystallization includes oxygen-containing solvent in a concentration of 20 ppm to 2% by weight. The oxygen-containing solvent is selected from the group consisting of water, C1-6-alcohols, C1-6-carboxylic acids, C1-6-ketones, C1-6-aldehydes, C1-12-ethers, C1-12-esters and mixtures of two or more of the aforementioned solvents.

A process for purifying a crude composition includes a monoterpene compound selected from the group consisting of monocyclic monoterpene alcohols, monocyclic monoterpene ketones, bicyclic epoxy monoterpenes and mixtures of two or more of the aforementioned compounds, such as preferably a monocyclic monoterpene alcohol. The process comprises performing a layer crystallization with a melt of the crude composition, and the melt of the crude composition subjected to the layer crystallization includes oxygen-containing solvent in a concentration of 20 ppm to 2% by weight. The oxygen-containing solvent is selected from the group consisting of water, C1-6-alcohols, C1-6-carboxylic acids, C1-6-ketones, C1-6-aldehydes, C1-12-ethers, C1-12-esters and mixtures of two or more of the aforementioned solvents.

The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.